Contact
searchSearch
HMP Global
Login

Ovarian Cancer Excellence Forum

Ovarian Cancer
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Mostafa Eyada, MD, University of Texas, Medical Branch
Videos
Bevacizumab Plus Oral Cyclophosphamide Demonstrated Safety, Efficacy Among Patients With Recurrent Platinum-Resistant Ovarian Cancer
06/19/2024
Mostafa Eyada, MD
Mostafa Eyada, MD, describes a retrospective analysis assessing the safety and efficacy of bevacizumab plus oral cyclophosphamide among patients with recurrent high-grade platinum-resistant ovarian, fallopian tube, and primary peritoneal...
Mostafa Eyada, MD, describes a retrospective analysis assessing the safety and efficacy of bevacizumab plus oral cyclophosphamide among patients with recurrent high-grade platinum-resistant ovarian, fallopian tube, and primary peritoneal...
Mostafa Eyada, MD, describes a...
06/19/2024
Oncology
Frederik Marmé, PhD, Heidelberg University
Videos
Atezolizumab Plus Chemotherapy and Bevacizumab Did Not Improve Survival For Patients With Recurrent Platinum-Resistant Ovarian Cancer
06/13/2024
Frederik Marmé, MD, PhD
According to phase 3 data, the addition of atezolizumab to the standard regiment of bevacizumab plus non-platinum chemotherapy did not improve overall survival or progression-free survival among patients with recurrent platinum-resistant...
According to phase 3 data, the addition of atezolizumab to the standard regiment of bevacizumab plus non-platinum chemotherapy did not improve overall survival or progression-free survival among patients with recurrent platinum-resistant...
According to phase 3 data, the...
06/13/2024
Oncology
Bradley Monk, MD, FACOG
Conference Coverage
Use of PARP Inhibitors for Maintenance Therapy Among Patients With Advanced Epithelial Ovarian Cancer
05/08/2024

Featuring Bradley Monk, MD, FACOG

Featuring Bradley Monk, MD, FACOG ...
At the 2024 Great Debates and Updates in Women’s Oncology meeting, Bradley Monk, MD, FACOG, discussed PARP inhibitors and determining the optimal maintenance therapy for women with advanced epithelial ovarian cancer. 
At the 2024 Great Debates and Updates in Women’s Oncology meeting, Bradley Monk, MD, FACOG, discussed PARP inhibitors and determining the optimal maintenance therapy for women with advanced epithelial ovarian cancer. 
At the 2024 Great Debates and...
05/08/2024
Oncology
Bradley Monk, MD, University of Arizona School of Medicine
Videos
Mirvetuximab Soravtansine for Folate Receptor-Alpha High, Platinum-Resistant Ovarian Cancer
08/02/2023
Bradley Monk, MD, discusses the results from the phase 3 MIRASOL trial and shares insights about mirvetuximab soravtansine for folate receptor-alpha high, platinum-resistant ovarian cancer.
Bradley Monk, MD, discusses the results from the phase 3 MIRASOL trial and shares insights about mirvetuximab soravtansine for folate receptor-alpha high, platinum-resistant ovarian cancer.
Bradley Monk, MD, discusses the...
08/02/2023
Oncology
Kathleen Moore, MD, Stephenson Cancer Center
Videos
Mirvetuximab Soravtansine Improved Overall Survival for Patients With Folate Receptor Alpha-High Platinum-Resistant Ovarian Cancer
07/27/2023
At the 2023 ASCO Annual Meeting, Kathleen Moore, MD, shares results from the MIRASOL trial, evaluating mirvetuximab soravtansine among patients with folate recetor alpha-high platinum-resistant ovarian cancer.
At the 2023 ASCO Annual Meeting, Kathleen Moore, MD, shares results from the MIRASOL trial, evaluating mirvetuximab soravtansine among patients with folate recetor alpha-high platinum-resistant ovarian cancer.
At the 2023 ASCO Annual Meeting,...
07/27/2023
Oncology
Debra Richardson, MD, Stephenson Cancer Center
Videos
Real-World Effectiveness of PARP Inhibitor Maintenance Therapy for Patients With Advanced Ovarian Cancer
06/21/2023
Debra Richardson, MD, discusses results from a real-world analysis exploring the effectiveness of PARP inhibitor maintenance therapy in patients with advanced ovarian cancer, specifically defined by biomarker status.
Debra Richardson, MD, discusses results from a real-world analysis exploring the effectiveness of PARP inhibitor maintenance therapy in patients with advanced ovarian cancer, specifically defined by biomarker status.
Debra Richardson, MD, discusses...
06/21/2023
Oncology
Helene Blons, PhD, PharmD, Georges Pompidou Hospital
Videos
Impact of BRCA1 and RAD15 Methylation on Maintenance Olaparib Plus Bevacizumab Efficacy in Ovarian Cancer
06/16/2023
At the 2023 ASCO Annual Meeting, Helene Blons, PhD, PharmD, discusses results from an abstract addressing the impact of BRCA1 and RAD51 methylation on the efficacy of olaparib plus bevacizumab maintenance treatment, from the...
At the 2023 ASCO Annual Meeting, Helene Blons, PhD, PharmD, discusses results from an abstract addressing the impact of BRCA1 and RAD51 methylation on the efficacy of olaparib plus bevacizumab maintenance treatment, from the...
At the 2023 ASCO Annual Meeting,...
06/16/2023
Oncology
Michael Goodheart, MD, University of Iowa, Iowa City, Iowa
Videos
Identifying Effective Treatment Combinations for Low-Grade Serous Ovarian Cancer
05/12/2023
Michael Goodheart, MD, and Adam Dupuy, PhD, discuss the use of CRISPR technology to identify new potential treatment combinations for low-grade serous ovarian cancer.
Michael Goodheart, MD, and Adam Dupuy, PhD, discuss the use of CRISPR technology to identify new potential treatment combinations for low-grade serous ovarian cancer.
Michael Goodheart, MD, and Adam...
05/12/2023
Oncology
Aaron Praiss, MD, Memorial Sloan Kettering Cancer Center, New York, New York
Videos
Surgical Stress May Promote IL-6–Driven Tumor Progression in High-Grade Serous Ovarian Cancer
05/11/2023
At the SGO Annual Meeting on Women’s Cancer, Aaron Praiss, MD discusses the role surgical stress can play in promoting IL-6–driven tumor progression in high-grade serous ovarian cancer.
At the SGO Annual Meeting on Women’s Cancer, Aaron Praiss, MD discusses the role surgical stress can play in promoting IL-6–driven tumor progression in high-grade serous ovarian cancer.
At the SGO Annual Meeting on...
05/11/2023
Oncology
Ayesha Alvero, MD, C.S. Mott Center at Wayne State University, Detroit, Michigan
Videos
Novel Immunomodulatory Virus CARG-2020 for Recurrent Ovarian Cancer
05/10/2023
At the SGO Annual Meeting on Women’s Cancer, Ayesha Alvero, MD, discusses CARG-2020, and how it may be used to restore immunosurveillance and establish anti-tumoral immunological memory among patients with ovarian cancer.
At the SGO Annual Meeting on Women’s Cancer, Ayesha Alvero, MD, discusses CARG-2020, and how it may be used to restore immunosurveillance and establish anti-tumoral immunological memory among patients with ovarian cancer.
At the SGO Annual Meeting on...
05/10/2023
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use